keyword
MENU ▼
Read by QxMD icon Read
search

Generic drug pricing

keyword
https://www.readbyqxmd.com/read/28545614/-hera-quest-hta-evaluation-of-generic-pharmaceutical-products-to-improve-quality-economic-efficiency-patient-safety-and-transparency-in-drug-product-changes-in-hospitals
#1
Miriam Gyalrong-Steur, Anita Kellermann, Rudolf Bernard, Georg Berndt, Meike Bindemann, Elfriede Nusser-Rothermundt, Steffen Amann, Myga Brakebusch, Jörg Brüggmann, Eva Tydecks, Markus Müller, Frank Dörje, Eberhard Kochs, Rainer Riedel
In view of the rising cost pressure and an increasing number of drug shortages, switches between generic drug preparations have become a daily routine in hospitals. To ensure consistently high treatment quality and best possible patient safety, the equivalence of the new and the previous drug preparation must be ensured before any change in the purchase of pharmaceutical products takes place. So far, no easily usable, transparent and standardized instrument for this kind of comparison between generic drug products has been available...
April 2017: Zeitschrift Für Evidenz, Fortbildung und Qualität Im Gesundheitswesen
https://www.readbyqxmd.com/read/28542239/projected-savings-through-public-health-voluntary-licences-of-hiv-drugs-negotiated-by-the-medicines-patent-pool-mpp
#2
Sandeep Juneja, Aastha Gupta, Suerie Moon, Stephen Resch
The Medicines Patent Pool (MPP) was established in 2010 to ensure timely access to low-cost generic versions of patented antiretroviral (ARV) medicines in low- and middle-income countries (LMICs) through the negotiation of voluntary licences with patent holders. While robust data on the savings generated by MPP and other major global public health initiatives is important, it is also difficult to quantify. In this study, we estimate the savings generated by licences negotiated by the MPP for ARV medicines to treat HIV/AIDS in LMICs for the period 2010-2028 and generate a cost-benefit ratio-based on people living with HIV (PLHIVs) in any new countries which gain access to an ARV due to MPP licences and the price differential between originator's tiered price and generics price, within the period where that ARV is patented...
2017: PloS One
https://www.readbyqxmd.com/read/28531237/burden-of-neurological-diseases-in-the-us-revealed-by-web-searches
#3
Ricardo Baeza-Yates, Puneet Mohan Sangal, Pablo Villoslada
BACKGROUND: Analyzing the disease-related web searches of Internet users provides insight into the interests of the general population as well as the healthcare industry, which can be used to shape health care policies. METHODS: We analyzed the searches related to neurological diseases and drugs used in neurology using the most popular search engines in the US, Google and Bing/Yahoo. RESULTS: We found that the most frequently searched diseases were common diseases such as dementia or Attention Deficit/Hyperactivity Disorder (ADHD), as well as medium frequency diseases with high social impact such as Parkinson's disease, MS and ALS...
2017: PloS One
https://www.readbyqxmd.com/read/28522459/drug-company-aspen-faces-probe-over-hiking-generic-prices
#4
Nigel Hawkes
No abstract text is available yet for this article.
May 18, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28508248/endogenous-versus-exogenous-generic-reference-pricing-for-pharmaceuticals
#5
F Antoñanzas, C A Juárez-Castelló, R Rodríguez-Ibeas
In this paper we carry out a vertical differentiation duopoly model applied to pharmaceutical markets to analyze how endogenous and exogenous generic reference pricing influence competition between generic and branded drugs producers. Unlike the literature, we characterize for the exogenous case the equilibrium prices for all feasible relevant reference prices. Competition is enhanced after the introduction of a reference pricing system. We also compare both reference pricing systems on welfare grounds, assuming two different objective functions for health authorities: (i) standard social welfare and (ii) gross consumer surplus net of total pharmaceutical expenditures...
May 15, 2017: International Journal of Health Economics and Management
https://www.readbyqxmd.com/read/28503962/impact-of-price-deregulation-policy-on-the-affordability-of-essential-medicines-for-women-s-health-a-panel-data-analysis
#6
Junjie Liu, Liming Wang, Chenxi Liu, Xinping Zhang
BACKGROUND: A new policy which required deregulation on prices of off-patent medicines for women's health during procurement was introduced in China in September 2015. The current study examines this policy's impact on the affordability of essential medicines for women's health. METHODS: Based on product-level panel data, a fixed effect regression model is employed by using procurement records from Hubei Centralist Tender for Drug Purchase platform. In the model, Affordability was measured with prices...
May 15, 2017: Expert Review of Pharmacoeconomics & Outcomes Research
https://www.readbyqxmd.com/read/28485714/portugal-health-system-review
#7
Jorge de Almeida Simoes, Goncalo Figueiredo Augusto, Ines Fronteira, Cristina Hernandez-Quevedo
This analysis of the Portuguese health system reviews recent developments in organization and governance, health financing, health care provision, health reforms and health system performance. Overall health indicators such as life expectancy at birth and at age 65 years have shown a notable improvement over the last decades. However, these improvements have not been followed at the same pace by other important dimensions of health: child poverty and its consequences, mental health and quality of life after 65...
March 2017: Health Systems in Transition
https://www.readbyqxmd.com/read/28479840/new-user-fee-agreements-aim-at-ensuring-relief-from-high-drug-prices-but-trump-s-budget-proposal-threatens-to-upend-completed-negotiations
#8
Stephen Barlas
The next iterations of the Generic Drug User Fee Act and the Biosimilar User Fee Act are meant to encourage new generic and biosimilar products, but higher fees and budget reductions may threaten progress.
May 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28465293/new-law-to-control-prices-of-generic-drugs
#9
Deborah Cohen
No abstract text is available yet for this article.
May 2, 2017: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/28449884/a-rapidly-changing-global-medicines-environment-how-adaptable-are-funding-decision-making-systems
#10
Christine Leopold, Steven G Morgan, Anita K Wagner
BACKGROUND: With the launch of very highly priced therapies and sudden price increases of generics, pressures on health systems have drastically increased. OBJECTIVES: We aimed to elicit opinions of key decision makers responsible for national assessment and funding decisions on their experiences to adapt to these new realities. METHODS/SETTING: Through interviews with decision makers of pharmaceutical assessment and/or funding agencies, we describe the challenges systems are currently facing, systems' responses and systems' characteristics facilitating or hindering responses to changes and overarching topics for the future...
April 10, 2017: Health Policy
https://www.readbyqxmd.com/read/28445102/journey-of-generic-imatinib-a-case-study-in-oncology-drug-pricing
#11
Christopher T Chen, Aaron S Kesselheim
No abstract text is available yet for this article.
April 26, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28400255/association-of-authorized-generic-marketing-with-prescription-drug-spending-on-antidepressants-from-2000-to-2011
#12
Ning Cheng, Tannista Banerjee, Jingjing Qian, Richard A Hansen
OBJECTIVES: Prior research suggests that authorized generic drugs increase competition and decrease prices, but little empirical evidence supports this conclusion. This study evaluated the impact of authorized generic marketing on brand and generic prices. DESIGN: Longitudinal analysis of the household component of the Medical Expenditure Panel Survey. SETTING: Interview panels over 12 years, with a new panel each year. For each panel, 5 rounds of household interviews were conducted over 30 months...
April 8, 2017: Journal of the American Pharmacists Association: JAPhA
https://www.readbyqxmd.com/read/28392910/drug-shortages-in-israel-regulatory-perspectives-challenges-and-solutions
#13
Eyal Schwartzberg, Denize Ainbinder, Alla Vishkauzan, Ronni Gamzu
BACKGROUND: Pharmaceutical drug shortages (DSs) are a global problem which presents challenges to countries around the world. Shortages of pharmaceutical products may have a direct detrimental impact on public health and patients' wellbeing by causing delayed, or even lack of, treatment. Moreover, DSs may force both patients and caregivers to use unfamiliar drugs, which could lead to medication errors. The objective of our study was to analyze DSs in Israel during the years 2013-2015, assessing their etiology and exploring the steps taken for their mitigation and prevention...
2017: Israel Journal of Health Policy Research
https://www.readbyqxmd.com/read/28383299/a-cost-savings-analysis-of-a-candidate-universal-antiretroviral-regimen
#14
David Ripin, Vineet R Prabhu
PURPOSE OF REVIEW: Despite significant strides in tackling HIV/AIDS in low-income and middle-income countries (LMICs), many treatment shortcomings remain, with limited drug selection to patients emerging as a critical challenge. The potential cost-savings benefits of adopting newer drugs as near-universal first-line antiretroviral (ARV) regimens that also provide improved clinical outcomes are discussed. RECENT FINDINGS: In the near term, a fixed-dose combination of dolutegravir (DTG or D) with tenofovir disoproxil fumarate (TDF), and either lamivudine or emtricitabine (XTC), that is, tenofovir disoproxil fumarate/XTC/DTG (TXD) (X = XTC), could represent a near-universal first-line antiretroviral regimen offering significant clinical benefit, commodity savings, and overall health system savings...
April 5, 2017: Current Opinion in HIV and AIDS
https://www.readbyqxmd.com/read/28381916/republicans-resolve-to-address-high-drug-prices-rhetoric-meets-reality-with-ppaca-replacement
#15
Stephen Barlas
As legislation is drafted to replace Obamacare, pharmaceutical issues-including controlling drug prices, expanding or contracting drug access, and incentivizing the development of generic drugs-are expected to be at the forefront of debate.
April 2017: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/28377378/evaluation-of-racial-and-socioeconomic-disparities-in-medication-pricing-and-pharmacy-access-and-services
#16
Marie A Chisholm-Burns, Christina A Spivey, Justin Gatwood, Adam Wiss, Kenneth Hohmeier, Steven R Erickson
PURPOSE: Results of a study to determine if disparities in drug pricing, pharmacy services, and community pharmacy access exist in a Tennessee county with a predominantly minority population are reported. METHODS: A cross-sectional survey of community pharmacies in Shelby County, a jurisdiction with a total population more than 60% composed of racial and ethnic minority groups, was conducted. Data collection included "out-of-pocket" (i.e., cash purchase) prices for generic levothyroxine, methylphenidate, and hydrocodone-acetaminophen; pharmacy hours of operation; availability of selected pharmacy services; and ZIP code-level data on demographics and crime risk...
May 15, 2017: American Journal of Health-system Pharmacy: AJHP
https://www.readbyqxmd.com/read/28373759/insights-on-the-use-of-biosimilars-in-the-treatment-of-inflammatory-bowel-disease
#17
REVIEW
Michael K Zheng, David Q Shih, Gary C Chen
Biologic therapy, such as those that target tumor necrosis factor (TNF) signaling, has proven to be an efficacious method of treatment for patients with inflammatory bowel disease (IBD) with regards to symptom management and mucosal healing. However, the rising prevalence of IBD worldwide and the ever-increasing burden of biologic pharmaceuticals in the health care industry is alarming for insurance companies, clinicians, and patients. The impending patent expiry and the relatively high costs of biologics, particularly anti-TNF agents, have paved the way for biosimilar development for IBD...
March 21, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28359273/a-comparison-of-generic-drug-prices-in-seven-european-countries-a-methodological-analysis
#18
Olivier J Wouters, Panos G Kanavos
BACKGROUND: Policymakers and researchers frequently compare the prices of medicines between countries. Such comparisons often serve as barometers of how pricing and reimbursement policies are performing. The aim of this study was to examine methodological challenges to comparing generic drug prices. METHODS: We calculated all commonly used price indices based on 2013 IMS Health data on sales of 3156 generic drugs in seven European countries. RESULTS: There were large differences in generic drug prices between countries...
March 31, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28265347/value-added-medicines-what-value-repurposed-medicines-might-bring-to-society
#19
Mondher Toumi, Cécile Rémuzat
Background & objectives: Despite the wide interest surrounding drug repurposing, no common terminology has been yet agreed for these products and their full potential value is not always recognised and rewarded, creating a disincentive for further development. The objectives of the present study were to assess from a wide perspective which value drug repurposing might bring to society, but also to identify key obstacles for adoption of these medicines and to discuss policy recommendations. Methods: A preliminary comprehensive search was conducted to assess how the concept of drug repurposing was described in the literature...
2017: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/28259587/justifying-high-drug-prices-within-the-context-of-value-biologics-versus-generics
#20
EDITORIAL
Mark E Patterson, Dakota J Rosenfelt
No abstract text is available yet for this article.
February 16, 2017: Research in Social & Administrative Pharmacy: RSAP
keyword
keyword
67607
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"